Eli Lilly (LLY) is back in focus after outlining a US$3b, decade-long investment in China tied to its oral GLP-1 drug orforglipron, while separately pressing U.S. regulators on compounded tirzepatide safety.

Despite a series of obesity drug launches, access initiatives, legal headlines and this new US$3b China plan, Eli Lilly’s short term share price performance has cooled. The company has seen a 30 day share price decline of 5.28% and a year to date share price decline of 8.82%, while the 1 year total shareholder return of 21.99% and 3 year total shareholder return of just over 3x still point to strong longer run momentum.

If Eli Lilly’s GLP-1 news has you thinking more broadly about obesity and diabetes care, it could be a good moment to scan 33 healthcare AI stocks for other potential ideas in this space.

With Eli Lilly trading at US$985.08 against an average analyst target of about US$1,216 and flagged as roughly 32% below one intrinsic value estimate, you have to ask: is there still upside here, or has the market already priced in the future growth?

Most Popular Narrative: 17.2% Undervalued

According to a widely followed narrative on Simply Wall St, Eli Lilly’s fair value sits at $1,189.18, above the last close of $985.08, which raises a clear valuation gap for investors to weigh.

Revenue growth of 20% to 25% per annum for the next 3 to 5 years due to lack of competition in the marketplace. Expecting production capacity to be sorted in the next few years, which will increase units shipped and lower operating costs as time goes on. The 10+ year time frame is still unknown due to new entrants. Confidence in this time frame is low. Based on this forecast and a discount of 9%, using the valuator tool puts the share price at around $1,200 USD.

Want to see how those aggressive growth and margin assumptions stack up against Eli Lilly’s current price? The narrative leans heavily on compounding volume, expanding profitability and a premium future earnings multiple. It may be useful to consider which specific time frame, and mix of obesity and diabetes sales, are contributing most to that fair value. The full story is in the detailed projections, not the headline number.

Result: Fair Value of $1,189.18 (UNDERVALUED)

However, there are still some big ifs here, including potential pricing pressure on GLP-1s and any safety or side effect issues that could curb long term demand.

Another View: High P/E As A Reality Check

That user narrative leans heavily on growth and a higher future earnings multiple, but the current P/E of 42.6x already sets a high bar. It is roughly in line with a fair ratio of 42.5x, yet well above the US Pharmaceuticals average of 17.4x and peer average of 18.5x, which suggests little room for error if growth or margins fall short.

Next Steps

Given all of that, are you feeling optimistic or cautious about Eli Lilly right now? Act quickly, review the numbers yourself, and weigh the balance of 4 key rewards and 2 important warning signs before making up your mind.

Looking for more investment ideas?

If Eli Lilly has sharpened your focus, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Spot potential bargains early by scanning screener containing 26 high quality undiscovered gems that many investors may not be paying close attention to yet.
• Strengthen the quality of your portfolio by reviewing companies in the solid balance sheet and fundamentals stocks screener (42 results) that pair financial resilience with fundamental support.
• Target cash flow today by checking out 14 dividend fortresses that may appeal if you are focused on income and stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.